Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL) A Placebo-controlled, Double-Blind Study

被引:67
作者
Pineros, Yanaika S. Sabogal [1 ,2 ]
Bal, Suzanne M. [1 ,2 ]
van de Pol, Marianne A. [2 ]
Dierdorp, Barbara S. [2 ]
Dekker, Tamara [2 ]
Dijkhuis, Annemiek [2 ]
Brinkman, Paul [1 ]
van der Sluijs, Koen F. [2 ]
Zwinderman, Aeilko H. [3 ]
Majoor, Christof J. [1 ]
Bonta, Peter I. [1 ]
Ravanetti, Lara [1 ,2 ]
Sterk, Peter J. [1 ]
Lutter, Rene [1 ,2 ]
机构
[1] Univ Amsterdam, Amsterdam UMC, Dept Resp Med, Amsterdam, Netherlands
[2] Univ Amsterdam, Amsterdam UMC, Dept Expt Immunol, Amsterdam Infect & Immun Inst, Amsterdam, Netherlands
[3] Univ Amsterdam, Amsterdam UMC, Dept Clin Epidemiol Bioinformat & Biostat, Amsterdam, Netherlands
关键词
loss of asthma control; exacerbation; mepolizumab; rhinovirus; 16; challenge; EXHALED NITRIC-OXIDE; MAST-CELL; EOSINOPHILS; EXACERBATIONS; MEPOLIZUMAB; ACTIVATION; EXPRESSION; PHENOTYPES; RECEPTORS; IL-5;
D O I
10.1164/rccm.201803-0461OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: Eosinophils drive pathophysiology in stable and exacerbating eosinophilic asthma, and therefore treatment is focused on the reduction of eosinophil numbers. Mepolizumab, a humanized monoclonal antibody that neutralizes IL-5 and efficiently attenuates eosinophils, proved clinically effective in severe eosinophilic asthma but not in mild asthma. Objectives: To study the effect of mepolizumab on virus-induced immune responses in mild asthma. Methods: Patients with mild asthma, steroid-naive and randomized for eosinophil numbers, received 750 mg mepolizumab intravenously in a placebo-controlled double-blind trial, 2 weeks after which patients were challenged with rhinovirus (RV) 16. FEV1, FVC, fractional exhaled nitric oxide, symptom scores (asthma control score), viral load (PCR), eosinophil numbers, humoral (luminex, ELISA), and cellular (flow cytometry) immune parameters in blood, BAL fluid, and sputum, before and after mepolizumab and RV16, were assessed. Measurements and Main Results: Mepolizumab attenuated baseline blood eosinophils and their activation, attenuated trendwise sputum eosinophils, and enhanced circulating natural killer cells. Mepolizumab did not affect FEV1, FVC, and fractional exhaled nitric oxide, neither at baseline nor after RV16. On RV16 challenge mepolizumab did not prevent eosinophil activation but did enhance local B lymphocytes and macrophages and reduce neutrophils and their activation. Mepolizumab also enhanced secretory IgA and reduced tryptase in BAL fluid. Finally, mepolizumab affected particularly RV16-induced macrophage inflammatory protein-3a, vascular endothelial growth factor-A, and IL-1RA production in BAL fluid. Conclusions: Mepolizumab failed to prevent activation of remaining eosinophils and changed RV16-induced immune responses in mild asthma. Although these latter effects likely are caused by attenuated eosinophil numbers, we cannot exclude a role for basophils.
引用
收藏
页码:508 / 517
页数:10
相关论文
共 38 条
[21]   Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response [J].
Leckie, MJ ;
ten Brinke, A ;
Khan, J ;
Diamant, Z ;
O'Connor, BJ ;
Walls, CM ;
Mathur, AK ;
Cowley, HC ;
Chung, KF ;
Djukanovic, R ;
Hansel, TT ;
Holgate, T ;
Sterk, PJ ;
Barnes, PJ .
LANCET, 2000, 356 (9248) :2144-2148
[22]   Angilogenesis and remodeling of airway vasculature in chronic inflammation [J].
McDonald, DM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (10) :S39-S45
[23]   Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production [J].
Message, Simon D. ;
Laza-Stanca, Vasile ;
Mallia, Patrick ;
Parker, Hayley L. ;
Zhu, Jie ;
Kebadze, Tatiana ;
Contoli, Marco ;
Sanderson, Gwen ;
Kon, Onn M. ;
Papi, Alberto ;
Jeffery, Peter K. ;
Stanciu, Luminita A. ;
Johnston, Sebastian L. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (36) :13562-13567
[24]   Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia [J].
Nair, Parameswaran ;
Pizzichini, Marcia M. M. ;
Kjarsgaard, Melanie ;
Inman, Mark D. ;
Efthimiadis, Ann ;
Pizzichini, Emilio ;
Hargreave, Frederick E. ;
O'Byrne, Paul M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (10) :985-993
[25]   Interleukin-8 secretion and neutrophil recruitment accompanies induced sputum eosinophil activation in children with acute asthma [J].
Norzila, MZ ;
Fakes, K ;
Henry, RL ;
Simpson, J ;
Gibson, PG .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (03) :769-774
[26]   Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies [J].
Ortega, Hector G. ;
Yancey, Steven W. ;
Mayer, Bhabita ;
Gunsoy, Necdet B. ;
Keene, Oliver N. ;
Bleecker, Eugene R. ;
Brightling, Christopher E. ;
Pavord, Ian D. .
LANCET RESPIRATORY MEDICINE, 2016, 4 (07) :549-556
[27]   Activated mouse eosinophils protect against lethal respiratory virus infection [J].
Percopo, Caroline M. ;
Dyer, Kimberly D. ;
Ochkur, Sergei I. ;
Luo, Janice L. ;
Fischer, Elizabeth R. ;
Lee, James J. ;
Lee, Nancy A. ;
Domachowske, Joseph B. ;
Rosenberg, Helene F. .
BLOOD, 2014, 123 (05) :743-752
[28]   The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands [J].
Pesce, Silvia ;
Thoren, Fredrik B. ;
Cantoni, Claudia ;
Prato, Carola ;
Moretta, Lorenzo ;
Moretta, Alessandro ;
Marcenaro, Emanuela .
FRONTIERS IN IMMUNOLOGY, 2017, 8
[29]  
PINEROS YSS, 2018, AM J RESP CRIT CARE, V197
[30]   An early innate response underlies severe influenza-induced exacerbations of asthma in a novel steroid-insensitive and anti-IL-5-responsive mouse model [J].
Ravanetti, L. ;
Dijkhuis, A. ;
Pineros, Y. S. Sabogal ;
Bal, S. M. ;
Dierdorp, B. S. ;
Dekker, T. ;
Logiantara, A. ;
Adcock, I. M. ;
Rao, N. L. ;
Boon, L. ;
Villetti, G. ;
Sterk, P. J. ;
Facchinetti, F. ;
Lutter, R. .
ALLERGY, 2017, 72 (05) :737-753